JAN Stock Overview
A clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
JanOne Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.39 |
| 52 Week High | US$5.26 |
| 52 Week Low | US$0.22 |
| Beta | 2.04 |
| 1 Month Change | -7.38% |
| 3 Month Change | 232.35% |
| 1 Year Change | 202.68% |
| 3 Year Change | -48.71% |
| 5 Year Change | -38.36% |
| Change since IPO | -98.17% |
Recent News & Updates
JanOne Inc.'s (NASDAQ:JAN) Share Price Boosted 153% But Its Business Prospects Need A Lift Too
Mar 31
JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry
Feb 14Recent updates
JanOne Inc.'s (NASDAQ:JAN) Share Price Boosted 153% But Its Business Prospects Need A Lift Too
Mar 31JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry
Feb 14Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now
Oct 03JanOne to acquire Soin Therapeutics
Sep 16Does JanOne (NASDAQ:JAN) Have A Healthy Balance Sheet?
Aug 17Health Check: How Prudently Does JanOne (NASDAQ:JAN) Use Debt?
Mar 21Is JanOne (NASDAQ:JAN) Using Debt In A Risky Way?
Nov 19JanOne adds Nicholas Goeders to scientific advisory board
Jun 15JanOne advances toward initiation of mid-stage peripheral artery disease trial
Jun 08JanOne under pressure on pricing $6M stock offering
Jan 29Shareholder Returns
| JAN | US Commercial Services | US Market | |
|---|---|---|---|
| 7D | -15.5% | 0.4% | 1.6% |
| 1Y | 202.7% | 27.4% | 26.1% |
Return vs Industry: JAN exceeded the US Commercial Services industry which returned 27.4% over the past year.
Return vs Market: JAN exceeded the US Market which returned 26.1% over the past year.
Price Volatility
| JAN volatility | |
|---|---|
| JAN Average Weekly Movement | 26.0% |
| Commercial Services Industry Average Movement | 6.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: JAN's share price has been volatile over the past 3 months.
Volatility Over Time: JAN's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 5 | Tony Isaac | www.janone.com |
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. Its lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019.
JanOne Inc. Fundamentals Summary
| JAN fundamental statistics | |
|---|---|
| Market cap | US$31.61m |
| Earnings (TTM) | -US$18.58m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs JAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JAN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$18.58m |
| Earnings | -US$18.58m |
Last Reported Earnings
Mar 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.05 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 38.1% |
How did JAN perform over the long term?
See historical performance and comparison